Skip to main content

Yorvipath

Generic: Palopegteriparatide

Verified·Oct 26, 2026
Manufacturer
Ascendis
NDC
73362-100
RxCUI
2693637
Route
SUBCUTANEOUS
ICD-10 indication
E20.9

Affordability Check

How much will you actually pay for Yorvipath?

In 30 seconds, see every legitimate way to afford Yorvipath — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Yorvipath

What is this medication?

Yorvipath is a prescription medication indicated for the treatment of hypoparathyroidism in adult patients. This condition occurs when the parathyroid glands do not produce enough parathyroid hormone, which is necessary for maintaining healthy levels of calcium and phosphorus in the body. By replacing the missing hormone, this medication helps to stabilize these mineral levels and manage the chronic symptoms associated with the disorder.

The medication functions as a prodrug of parathyroid hormone and is designed to provide a continuous release of the hormone over a twenty-four-hour period. It is administered through a daily injection under the skin. This consistent delivery helps patients reduce their reliance on large amounts of oral calcium and active vitamin D supplements while improving their overall mineral balance and quality of life.

Copay & patient assistance

  • Patient Copay Amount: As little as $5 per month
  • Maximum Annual Benefit Limit: Up to $12,000
  • Core Eligibility Restrictions: Limited to patients with commercial health insurance. Patients enrolled in federal or state healthcare programs (including Medicaid, Medicare, Medigap, VA, DOD, or TRICARE) are ineligible. Offer is not valid for cash-paying patients.
  • RxBIN, PCN, and Group numbers: Not Publicly Available

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How Yorvipath appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-08-31).

Covered by plans

4%

239 of 5,499 plans

Most common tier

Tier 5

On 79% of covering formularies

Prior authorization required

100%

of covering formularies

TierFormularies on this tierShare
Tier 1 (preferred generic)5
17%
Tier 2 (generic)1
3%
Tier 5 (specialty)23
79%

Step therapy: 0% of formularies

Quantity limits: 59% of formularies

Coverage breadth: 29 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

PayerPAStep therapyCopay tier

—

Medicare Part D

———

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.